Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Baird Maintains Outperform on Doximity, Raises Price Target to $45

Author: Benzinga Newsdesk | September 17, 2024 07:13am
Baird analyst Vikram Kesavabhotla maintains Doximity (NYSE:DOCS) with a Outperform and raises the price target from $41 to $45.

Posted In: DOCS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist